This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
L

Development and Validation of RSClinN+ Tool for HR+/HER2- Node-Positive BC

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Lajos Pusztai
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Lajos Pusztai
788 views
June 17, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh

Featured Video

06:40
Lilly Medical Affairs

Communicating the Risk of Recurrence for Patients With HR+, HER2- Ea…

Feat. J. O’Shaughnessy

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

24:36

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

2024 ASCO® Annual Meeting Insights Hub

S. Aithal

173 views
09:34

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical Care …

2024 ASCO® Annual Meeting Insights Hub

M. Lipsyc-Sharf

302 views
05:06

ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastatic Br…

2024 ASCO® Annual Meeting Insights Hub

M. Bhave

463 views
View All

Related Videos

25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.1K views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.1K views
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.2K views
11:31

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

8.2K views
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.3K views
12:35

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views
03:40

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Integrity CE

A. Bardia

1.5K views
06:39

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

593 views
05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views
14:16

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views
17:39

2023 Menopause Update

Yale School of Medicine

M. Minkin

9.1K views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

756 views
05:43

Neoadjuvant Chemo for HR+ BC: Year in Review

Total Health

C. Ma

974 views
36:18

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

1.2K views
09:19

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Prem…

Insights from 2023 SABCS

K. Kalinsky

1.8K views
57:44

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

5.1K views
17:20

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

2.1K views
02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
27:01

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Scripps Health

S. Sammons

1.7K views
AUTOPLAY